Literature DB >> 232297

Effect of serum and blood on Enterobacteriaceae grown in the presence of subminimal inhibitory concentrations of ampicillin and mecillinam.

V Lorian, B A Atkinson.   

Abstract

Bacteria from the strains of five species of Enterobacteriaceae grown in the presence of subminimal inhibitory concentrations of ampicillin or mecillinam formed into filamentous or round cells. These filamentous and round cells as well as normal control bacteria were incubated with either fresh human serum or blood, the bactericidal effects of which were then determined. In most cases, the bactericidal effect of either serum or blood on filamentous or round cells was less than the effect on control cells. In some cases, the effect on these drug-exposed cells was similar to that on control cells, but in no instance was the effect greater for the drug-exposed cells than for the control cells. However, in all cases in which the bactericidal effect of either serum or blood on the control cells was greater than or equal to 99%, the bactericidal effect on the drug-exposed cells was close to 90%. Although drug-exposed cells were not much more resistant to the bactericidal effect of serum or blood than were normal bacteria, they clearly were not more susceptible to these effects.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 232297     DOI: 10.1093/clinids/1.5.797

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  13 in total

1.  Human granulocyte activity against moxalactam-induced filamentous forms of Pseudomonas aeruginosa.

Authors:  M C Hammer; A L Baltch; R P Smith; J V Conroy; M Bishop; P Michelsen; L Hill
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

2.  Effect of azlocillin and piperacillin in subinhibitory and inhibitory concentrations on Staphylococcus aureus and Pseudomonas aeruginosa in broth, in serum and in the presence of human polymorphonuclear leukocytes.

Authors:  M Bassler; W Depuis; E Utz; H M Just; F D Daschner
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

3.  [Bactericidal activity of azlocillin against Pseudomonas aeruginosa in human serum].

Authors:  H M Just; C P Speicher; M Bassler; F D Daschner
Journal:  Infection       Date:  1984 Nov-Dec       Impact factor: 3.553

Review 4.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

5.  Increased phagocytosis and killing of Escherichia coli treated with subinhibitory concentrations of cefamandole and gentamicin in isolated rat livers.

Authors:  A Andreana; P Perna; R Utili; M Dilillo; G Ruggiero
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

6.  Killing of oxacillin-exposed staphylococci in human polymorphonuclear leukocytes.

Authors:  V Lorian; B Atkinson
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

7.  Treatment of experimental Salmonella typhimurium infection with mecillinam and ampicillin.

Authors:  T Butler; C W Shuster; P Dixon
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

8.  Effects of subminimal inhibitory concentrations of chloramphenicol, erythromycin and penicillin on group A streptococci.

Authors:  J Michel; M Ferne; R Borinski; Z Kornberg; S Bergner-Rabinowitz; I Ginsburg
Journal:  Eur J Clin Microbiol       Date:  1982-12       Impact factor: 3.267

9.  Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin.

Authors:  C G Gemmell; P K Peterson; D Schmeling; Y Kim; J Mathews; L Wannamaker; P G Quie
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

10.  Effect of subinhibitory concentrations of mecillinam on the serum susceptibility of Escherichia coli strains.

Authors:  P W Taylor; H Gaunt; F M Unger
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.